Coronavirus stock BioNTech (NASDAQ: BNTX) was a winner on Monday. BioNTech announced Monday that it has launched a project aimed at developing a malaria vaccine based on the messenger RNA (mRNA) technology that underpins BNT162b2. The biotech said this program, "will assess multiple vaccine candidates featuring known Malaria targets ... as well as new antigens discovered in the pre-clinical research phase."
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting